New applications of old metal-binding drugs in the treatment of human cancer

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 1, 2012, Pages 375-391

  Schmitt, Sara M ^a,b   Frezza, Michael ^a   Dou, Qing Ping ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chymotrypsin like activity; Clioquinol; Copper; Disulfiram; Dithiocarbamates; Proteasome inhibitor; Review; Ubiquitin proteasome pathway; Zinc

Indexed keywords

8 QUINOLINOL DERIVATIVE; ANTINEOPLASTIC METAL COMPLEX; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CLIOQUINOL; COPPER; COPPER DERIVATIVE; CYANOCOBALAMIN; DIETHYLDITHIOCARBAMIC ACID; DISULFIRAM; DITHIOCARBAMIC ACID DERIVATIVE; GLUCONATE COPPER; GOLD DERIVATIVE; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; NAMI A; OXALIPLATIN; PROTEASOME; PYRROLIDINEDITHIOCARBAMIC ACID; RUTHENIUM DERIVATIVE; UBIQUITIN; UNCLASSIFIED DRUG; ZINC; ZINC DERIVATIVE; ANTINEOPLASTIC AGENT; CHELATING AGENT; COORDINATION COMPOUND;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOLISM; ALZHEIMER DISEASE; AMEBIASIS; AMYLOID PLAQUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; BLADDER CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; COLORECTAL CANCER; COMPLEX FORMATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HUNTINGTON CHOREA; IC 50; LIVER METASTASIS; LUNG CANCER; LYMPHOMA; MANTLE CELL LYMPHOMA; MELANOMA; METASTATIC MELANOMA; MULTIPLE MYELOMA; MYCOSIS; NONHUMAN; OPTIC NERVE DISEASE; OVARY CANCER; OXIDATIVE STRESS; RENAL PROTECTION; RHEUMATOID ARTHRITIS; SHIGELLOSIS; TESTIS CANCER; UBIQUITINATION; UTERINE CERVIX CANCER; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); METABOLISM; NEOPLASM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CHELATING AGENTS; CLINICAL TRIALS AS TOPIC; COORDINATION COMPLEXES; HUMANS; NEOPLASMS;

EID: 84869482208     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/274     Document Type: Article

References (139)

1. E. Wong and C. M. Giandomenico: Current status of platinum-based antitumor drugs. Chem Rev, 99(9), 2451-66 (1999)
2. S. Eckhardt: Recent progress in the development of anticancer agents. Curr Med Chem Anticancer Agents, 2(3), 419-39 (2002)
3. M. J. Abrams and B. A. Murrer: Metal compounds in therapy and diagnosis. Science, 261(5122), 725-30 (1993)
4. M. Galanski, V. B. Arion, M. A. Jakupec and B. K. Keppler: Recent developments in the field of tumorinhibiting metal complexes. Curr Pharm Des, 9(25), 2078- 89 (2003)
5. M. Galanski, M. A. Jakupec and B. K. Keppler: Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem, 12(18), 2075-94 (2005)
6. A. Alama, B. Tasso, F. Novelli and F. Sparatore: Organometallic compounds in oncology: implications of novel organotins as antitumor agents. Drug Discov Today, 14(9-10), 500-8 (2009)
7. K. R. Harrap: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev, 12 Suppl A, 21-33 (1985)
8. A. de Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan and A. Bonetti: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18(16), 2938-47 (2000)
9. P. Calamai, S. Carotti, A. Guerri, T. Mazzei, L. Messori, E. Mini, P. Orioli and G. P. Speroni: Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin. Anticancer Drug Des, 13(1), 67-80 (1998)
10. G. Sava, S. Zorzet, T. Giraldi, G. Mestroni and G. Zassinovich: Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur J Cancer Clin Oncol, 20(6), 841-7 (1984)
11. P. Schluga, C. G. Hartinger, A. Egger, E. Reisner, M. Galanski, M. A. Jakupec and B. K. Keppler: Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans(14), 1796-802 (2006)
12. A. Bergamo, A. Masi, P. J. Dyson and G. Sava: Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol, 33(6), 1281-9 (2008)
13. T. Pieper, K. Borsky, B.K. Keppler: Non-platinum antitumor compounds. Top Biol Inorg Chem, 1, 171-199 (1999)
14. G. Sava, E. Alessio, A. Bergamo, G. Mestroni: Sulfoxide ruthernium complexes. Top Biol Inorg Chem, 1, 143-169 (1999)
15. G. Sava, S. Pacor, G. Mestroni and E. Alessio: Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis, 10(4), 273-80 (1992)
16. G. Sava, S. Pacor, A. Bergamo, M. Cocchietto, G. Mestroni and E. Alessio: Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chem Biol Interact, 95(1-2), 109-26 (1995)
17. M. A. Jakupec, V. B. Arion, S. Kapitza, E. Reisner, A. Eichinger, M. Pongratz, B. Marian, N. Graf von Keyserlingk and B. K. Keppler: KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development-an overview. Int J Clin Pharmacol Ther, 43(12), 595-6 (2005)
18. C. G. Hartinger, M. A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P. J. Dyson and B. K. Keppler: KP1019, a new redox-active anticancer agent-preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers, 5(10), 2140-55 (2008)
19. S. Apelgot, J. Coppey, A. Fromentin, E. Guille, M. F. Poupon and A. Roussel: Altered distribution of copper (64Cu) in tumor-bearing mice and rats. Anticancer Res, 6(2), 159-64 (1986)
20. M. Zowczak, M. Iskra, L. Torlinski and S. Cofta: Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res, 82(1-3), 1-8 (2001)
21. L. Turecky, P. Kalina, E. Uhlikova, S. Namerova and J. Krizko: Serum ceruloplasmin and copper levels in patients with primary brain tumors. Klin Wochenschr, 62(4), 187-9 (1984)
22. H. W. Kuo, S. F. Chen, C. C. Wu, D. R. Chen and J. H. Lee: Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res, 89(1), 1-11 (2002)
23. S. L. Rizk and H. H. Sky-Peck: Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res, 44(11), 5390-4 (1984)
24. S. B. Nayak, V. R. Bhat, D. Upadhyay and S. L. Udupa: Copper and ceruloplasmin status in serum of prostate and colon cancer patients. Indian J Physiol Pharmacol, 47(1), 108-10 (2003)
25. M. Diez, M. Arroyo, F. J. Cerdan, M. Munoz, M. A. Martin and J. L. Balibrea: Serum and tissue trace metal levels in lung cancer. Oncology, 46(4), 230-4 (1989)
26. F. K. Habib, T. C. Dembinski and S. R. Stitch: The zinc and copper content of blood leucocytes and plasma from patients with benign and malignant prostates. Clin Chim Acta, 104(3), 329-35 (1980)
27. B. R. McAuslan and W. Reilly: Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res, 130(1), 147-57 (1980)
28. P. M. Gullino: Considerations on the mechanism of the angiogenic response. Anticancer Res, 6(2), 153-8 (1986)
29. G. F. Hu: Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem, 69(3), 326- 35 (1998)
30. A. Veeravagu, A. R. Hsu, W. Cai, L. C. Hou, V. C. Tse and X. Chen: Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discov, 2(1), 59-71 (2007)
31. M. Frangoulis, P. Georgiou, C. Chrisostomidis, D. Perrea, I. Dontas, N. Kavantzas, A. Kostakis and O. Papadopoulos: Rat epigastric flap survival and VEGF expression after local copper application. Plast Reconstr Surg, 119(3), 837-43 (2007)
32. C. K. Sen, S. Khanna, M. Venojarvi, P. Trikha, E. C. Ellison, T. K. Hunt and S. Roy: Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol, 282(5), H1821-7 (2002)
33. A. Nasulewicz, A. Mazur and A. Opolski: Role of copper in tumour angiogenesis-clinical implications. J Trace Elem Med Biol, 18(1), 1-8 (2004)
34. M. Moriguchi, T. Nakajima, H. Kimura, T. Watanabe, H. Takashima, Y. Mitsumoto, T. Katagishi, T. Okanoue and K. Kagawa: The copper chelator trientine has an antiangiogenic effect against hepatocellular carcinoma, possibly through inhibition of interleukin-8 production. Int J Cancer, 102(5), 445-52 (2002)
35. S. Brem: Angiogenesis and Cancer Control: From Concept to Therapeutic Trial. Cancer Control, 6(5), 436- 458 (1999)
36. G. J. Brewer: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood), 226(7), 665-73 (2001)
37. S. A. Lowndes and A. L. Harris: The role of copper in tumour angiogenesis. J Mammary Gland Biol Neoplasia, 10(4), 299-310 (2005)
38. T. Theophanides and J. Anastassopoulou: Copper and carcinogenesis. Crit Rev Oncol Hematol, 42(1), 57-64 (2002)
39. J. Folkman: Tumor angiogenesis: therapeutic implications. N Engl J Med, 285(21), 1182-6 (1971)
40. J. Folkman: Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg, 175(3), 409-16 (1972)
41. Q. Pan, C. G. Kleer, K. L. van Golen, J. Irani, K. M. Bottema, C. Bias, M. De Carvalho, E. A. Mesri, D. M. Robins, R. D. Dick, G. J. Brewer and S. D. Merajver: Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res, 62(17), 4854-9 (2002)
42. J. Yoshii, H. Yoshiji, S. Kuriyama, Y. Ikenaka, R. Noguchi, H. Okuda, H. Tsujinoue, T. Nakatani, H. Kishida, D. Nakae, D. E. Gomez, M. S. De Lorenzo, A. M. Tejera and H. Fukui: The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int J Cancer, 94(6), 768-73 (2001)
43. K. L. Chang, T. C. Hung, B. S. Hsieh, Y. H. Chen, T. F. Chen and H. L. Cheng: Zinc at pharmacologic concentrations affects cytokine expression and induces apoptosis of human peripheral blood mononuclear cells. Nutrition, 22(5), 465-74 (2006)
44. R. B. Franklin and L. C. Costello: The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem, 106(5), 750-7 (2009)
45. M. Provinciali, G. Di Stefano and N. Fabris: Dosedependent opposite effect of zinc on apoptosis in mouse thymocytes. Int J Immunopharmacol, 17(9), 735-44 (1995)
46. M. Murakami and T. Hirano: Intracellular zinc homeostasis and zinc signaling. Cancer Sci, 99(8), 1515-22 (2008)
47. A. Federico, P. Iodice, P. Federico, A. Del Rio, M. C. Mellone and G. Catalano: Effects of selenium and zinc supplementation on nutritional status in patients with cancer of digestive tract. Eur J Clin Nutr, 55(4), 293-7 (2001)
48. A. S. Prasad, F. W. Beck, T. D. Doerr, F. H. Shamsa, H. S. Penny, S. C. Marks, J. Kaplan, O. Kucuk and R. H. Mathog: Nutritional and zinc status of head and neck cancer patients: an interpretive review. J Am Coll Nutr, 17(5), 409-18 (1998)
49. P. K. Chakravarty, A. Ghosh and J. R. Chowdhury: Zinc in human malignancies. Neoplasma, 33(1), 85-90 (1986)
50. R. B. Franklin and L. C. Costello: Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys, 463(2), 211-7 (2007)
51. S. K. Gupta, S. P. Singh and V. K. Shukla: Copper, zinc, and Cu/Zn ratio in carcinoma of the gallbladder. J Surg Oncol, 91(3), 204-8 (2005)
52. E. J. Margalioth, J. G. Schenker and M. Chevion: Copper and zinc levels in normal and malignant tissues. Cancer, 52(5), 868-72 (1983)
53. A. E. Schwartz, G. W. Leddicotte, R. W. Fink and E. W. Friedman: Trace elements in noraml and malignant human breast tissue. Surgery, 76(2), 325-9 (1974)
54. H. Zhao and D. Eide: The yeast ZRT1 gene encodes the zinc transporter protein of a high-affinity uptake system induced by zinc limitation. Proc Natl Acad Sci U S A, 93(6), 2454-8 (1996)
55. M. Li, Y. Zhang, Z. Liu, U. Bharadwaj, H. Wang, X. Wang, S. Zhang, J. P. Liuzzi, S. M. Chang, R. J. Cousins, W. E. Fisher, F. C. Brunicardi, C. D. Logsdon, C. Chen and Q. Yao: Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci U S A, 104(47), 18636-41 (2007)
56. L. C. Costello and R. B. Franklin: The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer, 5, 17 (2006)
57. D. L. Manning, J. F. Robertson, I. O. Ellis, C. W. Elston, R. A. McClelland, J. M. Gee, R. J. Jones, C. D. Green, P. Cannon, R. W. Blamey and et al.: Oestrogenregulated genes in breast cancer: association of pLIV1 with lymph node involvement. Eur J Cancer, 30A(5), 675-8 (1994)
58. K. M. Taylor, H. E. Morgan, K. Smart, N. M. Zahari, S. Pumford, I. O. Ellis, J. F. Robertson and R. I. Nicholson: The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Mol Med, 13(7-8), 396-406 (2007)
59. J. J. Christiansen and A. K. Rajasekaran: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res, 66(17), 8319-26 (2006)
60. A. Ciehanover, Y. Hod and A. Hershko: A heatstable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun, 81(4), 1100-5 (1978)
61. A. Hershko, A. Ciechanover, H. Heller, A. L. Haas and I. A. Rose: Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A, 77(4), 1783-6 (1980)
62. G. Nalepa, M. Rolfe and J. W. Harper: Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov, 5(7), 596-613 (2006)
63. A. Ciechanover: The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J, 17(24), 7151-60 (1998)
64. J. Adams: The proteasome: a suitable antineoplastic target. Nat Rev Cancer, 4(5), 349-60 (2004)
65. J. M. Peters, Z. Cejka, J. R. Harris, J. A. Kleinschmidt and W. Baumeister: Structural features of the 26 S proteasome complex. J Mol Biol, 234(4), 932-7 (1993)
66. W. Baumeister, J. Walz, F. Zuhl and E. Seemuller: The proteasome: paradigm of a self-compartmentalizing protease. Cell, 92(3), 367-80 (1998)
67. M. Groll, L. Ditzel, J. Lowe, D. Stock, M. Bochtler, H. D. Bartunik and R. Huber: Structure of 20S proteasome from yeast at 2.4 A resolution. Nature, 386(6624), 463-71 (1997)
68. M. Groll, W. Heinemeyer, S. Jager, T. Ullrich, M. Bochtler, D. H. Wolf and R. Huber: The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci U S A, 96(20), 10976-83 (1999)
69. G. N. DeMartino and C. A. Slaughter: The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem, 274(32), 22123-6 (1999)
70. A. L. Goldberg, P. Cascio, T. Saric and K. L. Rock: The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Mol Immunol, 39(3-4), 147-64 (2002)
71. O. Coux, K. Tanaka and A. L. Goldberg: Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem, 65, 801-47 (1996)
72. D. Nandi, P. Tahiliani, A. Kumar and D. Chandu: The ubiquitin-proteasome system. J Biosci, 31(1), 137-55 (2006)
73. J. Adams: The proteasome: structure, function, and role in the cell. Cancer Treat Rev, 29 Suppl 1, 3-9 (2003)
74. A. Ciechanover, A. Orian and A. L. Schwartz: Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays, 22(5), 442-51 (2000)
75. A. Ciechanover: The ubiquitin proteolytic system: from a vague idea, through basic mechanisms, and onto human diseases and drug targeting. Neurology, 66(2 Suppl 1), S7- 19 (2006)
76. J. Adams: The development of proteasome inhibitors as anticancer drugs. Cancer Cell, 5(5), 417-21 (2004)
77. L. Smith, M. J. Lind, P. J. Drew and L. Cawkwell: The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy. Eur J Cancer, 43(16), 2330-8 (2007)
78. Q. P. Dou and B. Li: Proteasome inhibitors as potential novel anticancer agents. Drug Resist Updat, 2(4), 215-223 (1999)
79. B. Li and Q. P. Dou: Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A, 97(8), 3850-5 (2000)
80. M. Loda, B. Cukor, S. W. Tam, P. Lavin, M. Fiorentino, G. F. Draetta, J. M. Jessup and M. Pagano: Increased proteasome-dependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med, 3(2), 231-4 (1997)
81. A. Kumatori, K. Tanaka, N. Inamura, S. Sone, T. Ogura, T. Matsumoto, T. Tachikawa, S. Shin and A. Ichihara: Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci U S A, 87(18), 7071-5 (1990)
82. B. An, R. H. Goldfarb, R. Siman and Q. P. Dou: Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ, 5(12), 1062-75 (1998)
83. U. G. Lopes, P. Erhardt, R. Yao and G. M. Cooper: p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem, 272(20), 12893-6 (1997)
84. R. Z. Orlowski and D. J. Kuhn: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res, 14(6), 1649-57 (2008)
85. T. Hideshima, P. Richardson, D. Chauhan, V. J. Palombella, P. J. Elliott, J. Adams and K. C. Anderson: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res, 61(7), 3071-6 (2001)
86. J. Adams, V. J. Palombella, E. A. Sausville, J. Johnson, A. Destree, D. D. Lazarus, J. Maas, C. S. Pien, S. Prakash and P. J. Elliott: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res, 59(11), 2615-22 (1999)
87. A. Frankel, S. Man, P. Elliott, J. Adams and R. S. Kerbel: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res, 6(9), 3719- 28 (2000)
88. R. C. Kane, P. F. Bross, A. T. Farrell and R. Pazdur: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist, 8(6), 508-13 (2003)
89. R. C. Kane, R. Dagher, A. Farrell, C. W. Ko, R. Sridhara, R. Justice and R. Pazdur: Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res, 13(18 Pt 1), 5291-4 (2007)
90. L. J. Crawford, B. Walker, H. Ovaa, D. Chauhan, K. C. Anderson, T. C. Morris and A. E. Irvine: Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res, 66(12), 6379-86 (2006)
91. R. Z. Orlowski and A. S. Baldwin, Jr.: NF-kappaB as a therapeutic target in cancer. Trends Mol Med, 8(8), 385-9 (2002)
92. S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis and D. J. McConkey: Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther, 2(9), 835-43 (2003)
93. B. A. Teicher, G. Ara, R. Herbst, V. J. Palombella and J. Adams: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res, 5(9), 2638-45 (1999)
94. A. Sartore-Bianchi, F. Gasparri, A. Galvani, L. Nici, J. W. Darnowski, D. Barbone, D. A. Fennell, G. Gaudino, C. Porta and L. Mutti: Bortezomib inhibits nuclear factorkappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res, 13(19), 5942-51 (2007)
95. M. Michaelis, I. Fichtner, D. Behrens, W. Haider, F. Rothweiler, A. Mack, J. Cinatl, H. W. Doerr and J. Cinatl, Jr.: Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol, 28(2), 439-46 (2006)
96. P. G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, D. Siegel, R. Z. Orlowski, D. Kuter, S. A. Limentani, S. Lee, T. Hideshima, D. L. Esseltine, M. Kauffman, J. Adams, D. P. Schenkein and K. C. Anderson: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med, 348(26), 2609-17 (2003)
97. S. Jagannath, B. G. Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, A. Mazumder, D. Schenkein and J. Crowley: Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol, 129(6), 776-83 (2005)
98. R. Z. Orlowski, P. M. Voorhees, R. A. Garcia, M. D. Hall, F. J. Kudrik, T. Allred, A. R. Johri, P. E. Jones, A. Ivanova, H. W. Van Deventer, D. A. Gabriel, T. C. Shea, B. S. Mitchell, J. Adams, D. L. Esseltine, E. G. Trehu, M. Green, M. J. Lehman, S. Natoli, J. M. Collins, C. M. Lindley and E. C. Dees: Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105(8), 3058-65 (2005)
99. E. B. Golden, P. Y. Lam, A. Kardosh, K. J. Gaffney, E. Cadenas, S. G. Louie, N. A. Petasis, T. C. Chen and A. H. Schonthal: Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood, 113(23), 5927-37 (2009)
100. T. Y. Kim, J. Park, B. Oh, H. J. Min, T. S. Jeong, J. H. Lee, C. Suh, J. W. Cheong, H. J. Kim, S. S. Yoon, S. B. Park and D. S. Lee: Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction. Br J Haematol, 146(3), 270- 81 (2009)
101. L. Malaguarnera, M. R. Pilastro, R. DiMarco, C. Scifo, M. Renis, M. C. Mazzarino and A. Messina: Cell death in human acute myelogenous leukemic cells induced by pyrrolidinedithiocarbamate. Apoptosis, 8(5), 539-45 (2003)
102. R. Schreck, B. Meier, D. N. Mannel, W. Droge and P. A. Baeuerle: Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med, 175(5), 1181-94 (1992)
103. J. Forestier: Rheumatoid arthritis and its treatment with gold salts - results of six years' experience. J Lab Clin Med, 20, 827-840 (1935)
104. E. R. Tiekink: Gold derivatives for cancer treatment. Bioinorg Chem Applns, 53, 1-9 (2003)
105. C. K. Mirabelli, R. K. Johnson, D. T. Hill, L. F. Faucette, G. R. Girard, G. Y. Kuo, C. M. Sung and S. T. Crooke: Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J Med Chem, 29(2), 218-23 (1986)
106. V. Milacic, D. Fregona and Q. P. Dou: Gold complexes as prospective metal-based anticancer drugs. Histol Histopathol, 23(1), 101-8 (2008)
107. P. J. Sadler and R. E. Sue: The chemistry of gold drugs. Met Based Drugs, 1(2-3), 107-44 (1994)
108. S. P. Fricker: A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes. Met Based Drugs, 6(4-5), 291-300 (1999)
109. L. Ronconi, L. Giovagnini, C. Marzano, F. Bettio, R. Graziani, G. Pilloni and D. Fregona: Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. Inorg Chem, 44(6), 1867-81 (2005)
110. L. Ronconi, C. Marzano, P. Zanello, M. Corsini, G. Miolo, C. Macca, A. Trevisan and D. Fregona: Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties. J Med Chem, 49(5), 1648-57 (2006)
111. L. Messori, G. Marcon and P. Orioli: Gold(III) compounds as new family of anticancer drugs. Bioinorg Chem Appl, 177-87 (2003)
112. D. L. Bodenner, P. C. Dedon, P. C. Keng and R. F. Borch: Effect of diethyldithiocarbamate on cisdiamminedichloroplatinum( II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition. Cancer Res, 46(6), 2745-50 (1986)
113. H. Huang, L. Zhu, B. R. Reid, G. P. Drobny and P. B. Hopkins: Solution structure of a cisplatin-induced DNA interstrand cross-link. Science, 270(5243), 1842-5 (1995)
114. V. Milacic, D. Chen, L. Ronconi, K. R. Landis- Piwowar, D. Fregona and Q. P. Dou: A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts. Cancer Res, 66(21), 10478-86 (2006)
115. X. Zhang, M. Frezza, V. Milacic, L. Ronconi, Y. Fan, C. Bi, D. Fregona and Q. P. Dou: Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. J Cell Biochem, 109(1), 162-72 (2010)
116. B. Johansson: A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl, 369, 15-26 (1992)
117. R. C. Vallari and R. Pietruszko: Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram. Science, 216(4546), 637-9 (1982)
118. R. E. Meyer: Prospects for a rational pharmacotherapy of alcoholism. J Clin Psychiatry, 50(11), 403-12 (1989)
119. D. Cen, D. Brayton, B. Shahandeh, F. L. Meyskens, Jr. and P. J. Farmer: Disulfiram facilitates intracellular Cu uptake and induces apoptosis in human melanoma cells. J Med Chem, 47(27), 6914-20 (2004)
120. D. Chen, Q. C. Cui, H. Yang and Q. P. Dou: Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res, 66(21), 10425-33 (2006)
121. S. S. Brar, C. Grigg, K. S. Wilson, W. D. Holder, Jr., D. Dreau, C. Austin, M. Foster, A. J. Ghio, A. R. Whorton, G. W. Stowell, L. B. Whittall, R. R. Whittle, D. P. White and T. P. Kennedy: Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metaldependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther, 3(9), 1049-60 (2004)
122. M. Marikovsky, N. Nevo, E. Vadai and C. Harris- Cerruti: Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer, 97(1), 34-41 (2002)
123. E. C. Reisinger, P. Kern, M. Ernst, P. Bock, H. D. Flad and M. Dietrich: Inhibition of HIV progression by dithiocarb. German DTC Study Group. Lancet, 335(8691), 679-82 (1990)
124. C. S. Kaplan, E. A. Petersen, D. Yocum and E. M. Hersh: A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection. Life Sci, 45(22), iii-ix (1989)
125. B. Cvek, V. Milacic, J. Taraba and Q. P. Dou: Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. J Med Chem, 51(20), 6256-8 (2008)
126. R. Verma, L. Aravind, R. Oania, W. H. McDonald, J. R. Yates, 3rd, E. V. Koonin and R. J. Deshaies: Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science, 298(5593), 611-5 (2002)
127. M. Gallery, J. L. Blank, Y. Lin, J. A. Gutierrez, J. C. Pulido, D. Rappoli, S. Badola, M. Rolfe and K. J. Macbeth: The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol Cancer Ther, 6(1), 262-8 (2007)
128. V. Milacic, D. Chen, L. Giovagnini, A. Diez, D. Fregona and Q. P. Dou: Pyrrolidine dithiocarbamate-zinc(II) and - copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. Toxicol Appl Pharmacol, 231(1), 24-33 (2008)
129. R. A. Cherny, C. S. Atwood, M. E. Xilinas, D. N. Gray, W. D. Jones, C. A. McLean, K. J. Barnham, I. Volitakis, F. W. Fraser, Y. Kim, X. Huang, L. E. Goldstein, R. D. Moir, J. T. Lim, K. Beyreuther, H. Zheng, R. E. Tanzi, C. L. Masters and A. I. Bush: Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 30(3), 665-76 (2001)
130. B. Regland, W. Lehmann, I. Abedini, K. Blennow, M. Jonsson, I. Karlsson, M. Sjogren, A. Wallin, M. Xilinas and C. G. Gottfries: Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord, 12(6), 408-14 (2001)
131. C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q. X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi and C. L. Masters: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60(12), 1685-91 (2003)
132. C. W. Ritchie, A. I. Bush and C. L. Masters: Metalprotein attenuating compounds and Alzheimer's disease. Expert Opin Investig Drugs, 13(12), 1585-92 (2004)
133. T. Nguyen, A. Hamby and S. M. Massa: Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A, 102(33), 11840-5 (2005)
134. L. M. Gholz and W. L. Arons: Prophylaxis and Therapy of Amebiasis and Shigellosis with Iodochlorhydroxyquin. Am J Trop Med Hyg, 13, 396-401 (1964)
135. M. Di Vaira, C. Bazzicalupi, P. Orioli, L. Messori, B. Bruni and P. Zatta: Clioquinol, a drug for Alzheimer's disease specifically interfering with brain metal metabolism: structural characterization of its zinc(II) and copper(II) complexes. Inorg Chem, 43(13), 3795-7 (2004)
136. D. Chen, Q. C. Cui, H. Yang, R. A. Barrea, F. H. Sarkar, S. Sheng, B. Yan, G. P. Reddy and Q. P. Dou: Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasomeinhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts. Cancer Res, 67(4), 1636-44 (2007)
137. K. G. Daniel, P. Gupta, R. H. Harbach, W. C. Guida and Q. P. Dou: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol, 67(6), 1139-51 (2004)
138. V. Milacic, P. Jiao, B. Zhang, B. Yan and Q. P. Dou: Novel 8-hydroxylquinoline analogs induce copperdependent proteasome inhibition and cell death in human breast cancer cells. Int J Oncol, 35(6), 1481-91 (2009)
139. S. Zhai, L. Yang, Q. C. Cui, Y. Sun, Q. P. Dou and B. Yan: Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells. J Biol Inorg Chem, 15(2), 259-69 (2010)